NCT03080974View on ClinicalTrials.gov

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

June 1, 2025

Study Completion Date

April 1, 2026

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Nivolumab

Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.

PROCEDURE

Irreversible Electroporation

Non-thermal ablation of tumor

Trial Locations (1)

40202

RECRUITING

University of Louisville, Louisville

All Listed Sponsors
lead

University of Louisville

OTHER